{"ticker": {"uuid": "18951d8f-f4c6-449a-a382-55fa05c2c1b2", "symbol": "ETON", "name": "Eton Pharmaceuticals Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Drug Manufacturers - Specialty & Generic"}, "articles": [{"title": "Eton Pharmaceuticals (ETON) Could Be 18% Undervalued As Valuation Questions Build", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T01:02:24+00:00", "published_display": "15 Jul 2026 01:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) CEO exercises options and RSUs, increasing stake", "summary": "Eton Pharmaceuticals President & CEO Sean Brynjelsen increased his stake in the company by exercising employee stock options for 200,000 shares and converting 27,500 restricted stock units (RSUs) into common stock. Following these transactions, Brynjelsen directly holds 1,061,194", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-5e6a44b6457d.html", "source_name": "Stock Titan", "published_at": "2026-07-14T21:20:11", "published_display": "14 Jul 2026 21:20", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (NASDAQ: ETON) CBO converts 10,000 RSUs into common shares", "summary": "Eton Pharmaceuticals' Chief Business Officer, David Krempa, has exercised 10,000 Restricted Stock Units (RSUs), converting them into an equal number of common shares. These RSUs were part of a larger grant from July 12, 2022, vesting in equal annual installments. Following this t", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-2ffb6208da81.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:14:17", "published_display": "13 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (ETON) That Institutions Follow", "summary": "This article analyzes Eton Pharmaceuticals Inc. (NASDAQ: ETON) using AI-generated signals for institutional trading strategies. It highlights weak near-term sentiment but strong mid and long-term outlooks, identifying compelling upside potential with no resistance levels above th", "url": "https://news.stocktradersdaily.com/news_release/8/The_Technical_Signals_Behind_ETON_That_Institutions_Follow_071326034803_1783928883.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T04:11:14", "published_display": "13 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceutical(ETON.US) 10% Shareholder Sells US$4.77 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUm8ta1BLOU56UVY3cmFIbVhwb0w3RDdmVDJTd1c1Y3ppdFJYWVluSWNsOHN6aFZwWXpOQUNPdGZEWGRRakFuUUc4R0lFQS1WQjZsVzNsYUtDWHZWNll1NWk0cFJ0VnBEYk5RNlZESnR4NGZYVG5JR3o5UVJUUEszdjI5cE9xRTl2aTBTRk44clNVSlo0WHozZGx6S0VzM21DRTloR3ZCVl8?oc=5", "source_name": "Moomoo", "published_at": "2026-07-07T23:27:56+00:00", "published_display": "07 Jul 2026 23:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opaleye management sells $4.77m Eton Pharmaceuticals (ETON) stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNmpTdm1JSmxFWm1JVWJ3aWpRLWlmVzJnSUdWdEh2ZUdGN09hZEJVSGYtQ29kVURHQnpjZjV2NHdiOE5PaVZfTXM0YWZCaTZnNEF5VGNETHpHeDFZaWtqV3NKN3lnblRfY29WMFVPVmJOMWt6ZnZ0X2dqSFJkcER3Q1Qwal96ZHBReTFJVFAxeG43dTZucUdkRllFZHltQ3c5YkRYdXc5YmVSUDI3U3Y4d0gtNXhvWnZLdTlhRDFXT0tWMktK?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T23:06:16+00:00", "published_display": "07 Jul 2026 23:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opaleye trims Eton Pharmaceuticals (ETON) stake with open-market sales", "summary": "Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals (ETON), reported open-market sales of 126,685 shares of common stock between July 2 and July 7, 2026. The shares were sold at weighted average prices between $37 and $38, reducing Opaleye L.P.'s holdings to 2,680,000 sh", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-f17613f340a2.html", "source_name": "Stock Titan", "published_at": "2026-07-07T22:39:37", "published_display": "07 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals highlights its niche rare-disease focus as a specialty drug developer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPa3MxNDFDV3I4U28zQnRjZGZ3U1VwTkdHS0xBNFhFQ2hWSDZLX05OVWM2alozN3J1RFkySHlWeU9oa04zc3lwNEdyaE5qd2RoaXQ1ZW5FYVJlWFI2UTJkUjAzVzBSeDUwNXFidDN0c0xFdUJtLWZiN0FZaFdiVXdwTlljdTZ6ck1xT09wUUxmNmYxMGFyVS05T0VHRFFXbVNvblNmcy12WXktdHoxU0NJUzVuZDUzdWdKQXloNnB3dUFUQQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T18:00:21+00:00", "published_display": "07 Jul 2026 18:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals stock hits all-time high at 38.6 USD", "summary": "Eton Pharmaceuticals (ETON) stock reached an all-time high of $38.60, reflecting a 164.21% total return over the past year and nearly 80% revenue growth in the last twelve months. Despite an InvestingPro tip suggesting the stock might be overbought, the platform's Fair Value anal", "url": "https://www.investing.com/news/company-news/eton-pharmaceuticals-stock-hits-alltime-high-at-386-usd-93CH-4779704", "source_name": "Investing.com", "published_at": "2026-07-07T15:39:37", "published_display": "07 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) Grants Stock Awards, Is It Still 18% Below Fair Value?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Eton Pharmaceuticals Inc. (ETON) Risk Zones", "summary": "This article analyzes Eton Pharmaceuticals Inc. (ETON) using AI models to provide precision trading strategies. It highlights strong sentiment across all horizons, suggesting an overweight bias, and details institutional trading strategies for long, breakout, and short positions ", "url": "https://news.stocktradersdaily.com/news_release/10/Precision_Trading_with_Eton_Pharmaceuticals_Inc._ETON_Risk_Zones_070226024002_1782974402.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-03T01:40:53", "published_display": "03 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Eton Pharmaceuticals, Inc. \u2013 NASDAQ:ETON", "summary": "This article provides financial context for Eton Pharmaceuticals, Inc. (NASDAQ: ETON), focusing on its enterprise value to forward revenue. It is presented within the framework of TradingView's platform, offering an overview of the company's financial data. The content is concise", "url": "https://www.tradingview.com/symbols/NASDAQ-ETON/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T12:10:37", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) CBO awarded 10,000 restricted stock units", "summary": "Eton Pharmaceuticals' Chief Business Officer, David Krempa, was granted 10,000 restricted stock units (RSUs) as part of a compensation package. These RSUs will vest in four equal annual installments starting June 26, 2027, contingent on his continued employment. Following this gr", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-851ffc5cdabe.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:36", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Eton Pharmaceuticals Inc For: 30 June By Investing.com", "summary": "Investing.com reported on a Form 4 filing for Eton Pharmaceuticals Inc. as of June 30th. The brief article, published in the stock market section, mentioned the company's stock symbol ETON and its recent performance. It primarily serves as a notice of the regulatory filing and in", "url": "https://ca.investing.com/news/stock-market-news/form-4-eton-pharmaceuticals-inc-for-30-june-93CH-4714684", "source_name": "Investing.com Canada", "published_at": "2026-06-30T20:39:36", "published_display": "30 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals stock hits all-time high at 36.97 USD", "summary": "Eton Pharmaceuticals (ETON) stock has reached an all-time high of $36.97, marking a 161.1% increase over the past year and pushing its market capitalization to $1.01 billion. This surge reflects strong investor confidence despite a mixed Q1 2026 earnings report where revenue beat", "url": "https://m.uk.investing.com/news/stock-market-news/eton-pharmaceuticals-stock-hits-alltime-high-at-3697-usd-93CH-4750895?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-30T18:40:44", "published_display": "30 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Eton Pharmaceuticals, Inc. \u2013 BOATS:ETON", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Eton Pharmaceuticals, Inc. (ETON) listed on the Blue Ocean Alternative Trade System (BOATS). It provides a brief overview without detailed financial data or analysis. The content appears to be a stub or ", "url": "https://www.tradingview.com/symbols/BOATS-ETON/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:11:40", "published_display": "29 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Eton Pharmaceuticals, Inc. \u2013 NASDAQ:ETON", "summary": "This article provides the \"Price to sales forward\" metric for Eton Pharmaceuticals, Inc. (NASDAQ: ETON). It specifically highlights the period, value, and change percentages for this financial indicator, noting that the market was closed at the time of publication with no recent ", "url": "https://www.tradingview.com/symbols/NASDAQ-ETON/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:10:12", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Eton Pharmaceuticals, Inc. \u2013 BOATS:ETON", "summary": "The article focuses on the \"Enterprise value to EBITDA forward\" metric for Eton Pharmaceuticals, Inc. (ETON) on the Blue Ocean Alternative Trade System (BOATS). It presents a financial snapshot within the TradingView platform, indicating a market closed status with no recent trad", "url": "https://www.tradingview.com/symbols/BOATS-ETON/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:40:48", "published_display": "28 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Eton Pharmaceuticals, Inc. (ETON) stock for 2027, based on analyst opinions. It includes current stock performance metrics, financial data, and answers frequently asked questions regarding ETON's stock price, volatility, marke", "url": "https://www.tradingview.com/symbols/NASDAQ-ETON/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T22:12:00", "published_display": "26 Jun 2026 22:12", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON (ETON) Form 144: Affiliate sales include 25,000-share disposals", "summary": "Eton Pharmaceuticals (ETON) affiliate James R. Gruber filed a Form 144 revealing proposed and past sales of common stock, including three dispositions totaling 53,117 shares in June 2026. The filing also detailed various issuer-side equity transactions like stock option exercises", "url": "https://www.stocktitan.net/sec-filings/ETON/144-eton-pharmaceuticals-inc-sec-filing-fbfd04d5baab.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:39:28", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ETON)", "summary": "This article provides an overview of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates for earnings and revenue, analyst price targets, and future earnings re", "url": "https://www.tradingview.com/symbols/NASDAQ-ETON/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T18:39:28", "published_display": "26 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Eton Pharmaceuticals For: 25 June By Investing.com", "summary": "This article from Investing.com announces the Form 144 filing for Eton Pharmaceuticals on June 25, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article itself is very brief, serving primarily as an announcement", "url": "https://ng.investing.com/news/stock-market-news/form-144-eton-pharmaceuticals-for-25-june-93CH-2575103", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T09:40:46", "published_display": "26 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON (NASDAQ: ETON) notice: Director proposes sale of 25,000 shares", "summary": "A director at Eton Pharmaceuticals (NASDAQ: ETON) has filed a Form 144, indicating a proposed sale of 25,000 shares related to a stock option exercise on June 25, 2026. This filing also discloses previous sales by the same individual, James R. Gruber, including 25,000 shares on J", "url": "https://www.stocktitan.net/sec-filings/ETON/144-eton-pharmaceuticals-inc-sec-filing-3b41f6972d02.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:13:04", "published_display": "25 Jun 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Inc (ETON) Institutional Confidence", "summary": "Eton Pharmaceuticals Inc (ETON) has an institutional shareholding score of 5.00, ranking 73rd in the Pharmaceuticals industry. The institutional shareholding proportion is 58.43%, a decrease of 4.32% quarter-over-quarter. James Simons is the largest institutional shareholder, hol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eton/sentiment", "source_name": "TradingKey", "published_at": "2026-06-24T10:40:48", "published_display": "24 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider files to sell 25,000 shares via option exercise | ETON SEC Filing - Form 144", "summary": "An insider at Eton Pharmaceuticals (ETON) has filed a Form 144 to sell 25,000 shares through a stock option exercise scheduled for June 23, 2026. The filing also disclosed a prior sale of 3,117 shares on June 2, 2026, which generated $84,041.00. This administrative notice pertain", "url": "https://www.stocktitan.net/sec-filings/ETON/144-eton-pharmaceuticals-inc-sec-filing-aceef204cb1a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:41", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Eton Pharmaceuticals For: 23 June By Investing.com", "summary": "This article from Investing.com reports on the filing of Form 144 by Eton Pharmaceuticals on June 23. It includes the stock symbol ETON and its performance, showing a 2.35% increase. The piece is brief and simply states the form filing event.", "url": "https://ca.investing.com/news/stock-market-news/form-144-eton-pharmaceuticals-for-23-june-93CH-4704566", "source_name": "Investing.com Canada", "published_at": "2026-06-23T10:42:00", "published_display": "23 Jun 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc.(NasdaqGM:ETON) added to S&P Pharmaceuticals Select Industry Index", "summary": "Eton Pharmaceuticals, Inc. (NasdaqGM: ETON) has been added to the S&P Pharmaceuticals Select Industry Index. This news comes amidst recent insider stock sales, with one individual selling shares worth $1,623,795 on June 17, and another selling shares worth $3,229,923 on May 28. T", "url": "https://www.marketscreener.com/news/eton-pharmaceuticals-inc-nasdaqgm-eton-added-to-s-p-pharmaceuticals-select-industry-index-ce7f5cd3d88df620", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:40:19", "published_display": "22 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals director Adams sells 50,000 shares for $1.62m By Investing.com", "summary": "Jennifer McKie Adams, a director at Eton Pharmaceuticals (NASDAQ:ETON), sold 50,000 shares of the company\u2019s common stock for approximately $1.62 million on June 17, 2026, after exercising employee stock options. This transaction follows a 138% surge in ETON stock over the past ye", "url": "https://za.investing.com/news/insider-trading-news/eton-pharmaceuticals-director-adams-sells-50000-shares-for-162m-93CH-4333935", "source_name": "Investing.com South Africa", "published_at": "2026-06-18T19:39:18", "published_display": "18 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals director Adams sells 50,000 shares for $1.62m", "summary": "Jennifer McKie Adams, a director at Eton Pharmaceuticals, sold 50,000 shares of the company\u2019s common stock for approximately $1.62 million on June 17, 2026. This sale followed Adams exercising employee stock options at a much lower price. The company recently reported mixed Q1 20", "url": "https://m.uk.investing.com/news/insider-trading-news/eton-pharmaceuticals-director-adams-sells-50000-shares-for-162m-93CH-4734078?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T04:10:06", "published_display": "18 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Director Sold Shares Worth Over $1.6M", "summary": "Jennifer Mckie Adams, a Director at Eton Pharmaceuticals, sold 50,000 shares of common stock on June 17, 2026, for a total of $1,623,795. The shares were sold in multiple trades at an average price of $32.4759 per share. Following this transaction, the director no longer directly", "url": "https://www.tradingview.com/news/tradingview:5f309a69213cd:0-eton-pharmaceuticals-director-sold-shares-worth-over-1-6m/", "source_name": "TradingView", "published_at": "2026-06-17T21:09:33", "published_display": "17 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) director exercises options, sells 50,000 shares in open market", "summary": "Eton Pharmaceuticals director Jennifer McKie Adams exercised employee stock options for 50,000 shares at $3.78 per share and immediately sold them in open-market transactions for a weighted average price of $32.4759 per share. The sale, totaling over $1.6 million, occurred throug", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-e69630c3c934.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:33", "published_display": "17 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Insider Sold Shares Worth $1,623,795, According to a Recent SEC Filing", "summary": "An insider at Eton Pharmaceuticals recently sold shares valued at $1,623,795, as disclosed in a recent SEC filing. This transaction follows another significant insider sale on May 28, 2026, where shares worth $3,229,923 were sold. The company, focused on rare disease treatments, ", "url": "https://www.marketscreener.com/news/eton-pharmaceuticals-insider-sold-shares-worth-1-623-795-according-to-a-recent-sec-filing-ce7f5cddd889f52d", "source_name": "www.marketscreener.com", "published_at": "2026-06-17T21:09:32", "published_display": "17 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Insider Sold Shares Worth $3,229,923, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/eton-pharmaceuticals-insider-sold-shares-075022089.html", "source_name": "MT Newswires", "published_at": "2026-05-28T07:50:22+00:00", "published_display": "28 May 2026 07:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains Bullish on Eton Pharmaceuticals\u2019 (ETON) Growth Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNX2hZQjhadkNoeXBhTWM0dGo4S0dXamxXTzF3eWJHY2F4dFktdlR3MnZxSWhpSUQxNUFXejFQRUZNcy1VaERyTW5EeUo3aTBuYy0tcVFhSlVDMEUtdjRIbU9LQVh5QXc1NjJjVVFXV3ZDeHhxUlAtNko0RERwWGxGMDh5VmYxeUhsY1g1V25XemFjQ2c2OFYyOUNNMA?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Obtains US Commercialization Rights to Impavido", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eton-pharmaceuticals-obtains-us-commercialization-210741609.html", "source_name": "MT Newswires", "published_at": "2026-05-19T21:07:41+00:00", "published_display": "19 May 2026 21:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO\u00ae (miltefosine)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eton-pharmaceuticals-expands-rare-disease-203000534.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:30:00+00:00", "published_display": "19 May 2026 20:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Announces U.S. Commercialization Rights for IMPAVIDO\u00ae, First FDA-Approved Oral Therapy for Leishmaniasis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPbTVKeTVLbktaUjBIVE14YU1kb2poeHNUYzNQM3AzZUZuM1hrYnpGd1dfbzc3NGo2UWpTSGVoeTVBZjJTbXdIejVnS0d0UjBoS1g2bFc3REJ2R2RDLXY5SEFtNmQ0YkVza2pwbldiVW9rclhHaG1EOXl0bkoyNURlcGV0dmF4YTN6cHhBdW80LUNWeW00b1BCQ2lFRkFBa1Q5RWE2QmpaYVNYWHlKV2E1Y1lXZ0hPb1c1dzNQV04wTlU3X0hyVnpjU1NfdU9tWFpEQmQ2MERoV3dYcURXeUl5a2VnUjF2dk5FMjlzd1VmQ3ZISGZJZUszSw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQZ0tPMGNUdWZQOEp6cDdIN2RlMGxrQl9HdDhkOTFtdnVEaVg1LXJDbFBaZ2p4NmZvVU5fdFZhdVJmbl9mZTVTak55NjhEQ01vZTl5MjFSendpOEFsN3FWRmM1T2RYLThqdERGQUVaV1cxMExZaTk5M25QSkRWWGJOMUUyTzVDMTJJbks0Mk1DQjI1Q3FpWDg3TE1sYmR4OXZZTFBJ?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/7d53c4ba-2771-3e8e-82e8-32ae12a0618f/eton-pharmaceuticals%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-15T12:30:00+00:00", "published_display": "15 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Inc (ETON) Q1 2026 Earnings Call Highlights: Record Sales and Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eton-pharmaceuticals-inc-eton-q1-050209376.html", "source_name": "GuruFocus.com", "published_at": "2026-05-15T05:02:09+00:00", "published_display": "15 May 2026 05:02", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVnRJMXJYSmlaSU9uVDc1ZXZoVVlXRV9VNVl2eENib1hjVllMRm9KelowbVYyNC1oamgwSWJLNjE2RjdTX3lfYnRxdGdSVFgtd1pzOUJuSDhHWTIwSnlCbEhKczdEcTctQlF2VDAtZ1FZYTZYTHNoM2xJZGd1NThxaDZvSjNlNDQ2SzBZdERsbGg4dnZyV2pReUt2em9DYjRUV1RRQ2d1TW9kMlA3QkNIYWMtYWhyZV9IYU9zUUlIMlpZd1pHV3pCMmNjUG11LVlmWjdN?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON PHARMACEUTICALS ($ETON) Releases Q1 2026 Earnings, Stock Rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOSmwzX1FMLVJDZkY1SHdrZUhjTzRLVUpXVHItOUdIVFFCTDVKd0xxT3NpeXIwT3JpNFp1clZKR0E0M0NNcWRpVThQWktYVEI1OVk5U1hIZGR3dkVuVHNQaVcxZ09LYnhKQ0J6a3dMSWNxZDIweXhtbWlVOWtHZmZwMW1VN3hsdnB3Nnh6bU1rZTFfNEJGZUVkVG9vNllSSUZocUVKc1ZHLWsxZldC?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPV3p5ZUlmNkJpRmZNWkRHSU56eU42ZXVlRlY0NnVwN1E0am9XbFdOdjNYbjEwWjJDTVVCYno5VFM0MHNvQlhxZE40MFJuUDdXVjFmYzhRRTk3UEtiT2tpQWlNUlBTR0tJNGpGTmNzX2VycjRlOXdvWWxSbmVYb2tBUTVsTWI0NXN4bG1nNkpBcHRkbkxLZHBBMW05WHFWa3lzd0Rz?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPUlhkUENyWlY2UzctUk5pd2c2OWNuRl9mUlZSWGRZX0JCN2xveExBRXF3clNMS0p4YzBDZWZKSEVJN0hlSVcwTVh3UGNOLU9hU1VBZ3B0bmNDbjBteHlYWWI5UGdoa01rNG5lVWpFaEcyMDdWeXNLaXA3QU1mYnFiYjFZNEF6elQ4OXFoRFhwZnlEeEpDcEh1UXEzREpuVHRFQ1E?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Hemangeol Deal Is Rewriting The Story For Eton Pharmaceuticals (ETON)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPVWUxV2dlNTJVam53VnZFQlh3TFNpc0R3dnVXbE5WNWJYYkF0azA3czFGaDZHSi1EZFptQXhXU1lmclFuN3ZjeHBzMktHLWctSjYwemdBM0Q4Tk5ET2piZ0owY21JRzRmZnV1akV2Y2V0NmM4X01wLVBlMHh2ZEhsTUlQbUt6aW14bzhUOGczYjI0OFNSYVRfdVlZb0loM2RkTnc?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Hemangeol Deal Is Reframing The Eton Pharmaceuticals (ETON) Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNMXdJeTBlU0d3X3JBYTYtb1FXOFc5R1gycnBEMWVJVzA3V1FEOWRHd0d2bjBCQk1nZlg2aV9jbTdQTkRQMjFEUnE5cHhleFBhb0YxeWZVQUhUSFFhRkY0UjlNWng4R0RENTZCMjVQTXA1bVlNRUphUndxMEk4NkNrMlNlRG44dzdFMlFsM1BHUGE5WHNDMFk3cmF2ZWtuUHBZSDdBNDNqQmNjd0o2NXlV?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Eton Pharmaceuticals (ETON) Story Is Shifting With Hemangeol And New Valuation Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNN2x2dThDZzhqb0xfZFdhVjQ1MG14UnpIRGk2Yl9MQzhNdXpCYkdFVXF0cDlRTzFkdXY5RUF6SEh4SmhwaDExVWhJdWI2a2Y4X1VGV0Y5cEw2MzMtdGRwMXVHbjBrQW92S1BTRUhTTkt1MWdhSUoydVNQRXNUTmp4YmVaQ3pfRTdqNmxwRmk2Q1pEei1rSEk3eURtczE2amxCNW16SmN1cTY?oc=5", "source_name": "Market source", "published_at": "2026-04-05T07:00:00+00:00", "published_display": "05 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNRndoa0JMLURRdlNDemQ0U3BKN1M2aVZUMnNZTGdXZFQtajUxWGJMQ0UxZXEyOFZHUVJpNDhtQU1VRVRTUnVvUHR6ZUhIWTA1TjFFWkEzUTQxQ0IyTEJFbTBLb1Vkay1wd0tYVnluampkZDl4bVhKaHo1U3pWdzlORnNHd0xkSDJxTGx6VWhibXItNkJPVmJWQkdTZFl0bmc?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Eton Pharmaceuticals Q4 2025 beats EPS, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQLVFBUTFOSU9JT0ViQUZNZjVJRjZTNC1rVm8tTTFDQk43MDBIRW9XVGpQRGIzUlZZZmtraTRmUGZYZHZFS0xmRFlobkpreXZzMnlEbGxicnRuQnhKOWY2NjBZcFVOemQ5SHBqTG15TDBNd1BQN2pJbVJKX1BQa3hPWVJ2NFZpa2VCeXFnbmpJNmVuTXlMcWt2S1VVcTVQTkJqMGl0UEdnYWZGaEt0TTVFYVBYVEs3T0ZaQkVQSUl0VzZWYWxRSEl4N1lldw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Expands Rare Disease Portfolio with Acquisition of US Hemangeol Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOOVFxZWxKakNERTRJY2liTjBJd1FscmtUMlNDRkhwT2ctY3hDVFRPSEtPZjUtT3VlR0R5a202aW10dUhnU0xUMWZBeWg2bVVhMTZxTmYzbGhacWVTQkJyTmVhUkNNY0JYcnQ1LUhBeXVNRDFadUNReHBTU2QzNFo3STRSeTUzYkQyZFZuYkZQdzRqWlB4eWZiTDREcXpvazRSRWJsY1B1TjdYVTZLaS1ma3RJQ0pjNFk5X2llYjN0RTlvY3VDaG1XYVlxNGtiY2VX?oc=5", "source_name": "Pharmaceutical Commerce", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals: An Undervalued Small Cap With High Growth (NASDAQ:ETON)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNOGxleHlzMVRmLTJJZUpQaG1wVy13SnZianVSbDlwbm9yMUtWU0pJeEZZNEduVkE2RUJJaTRkdy1DbzNmSjY1LS0zRi1EZGU3OVlCeUpvV01lQ1loTUZVbDZvNThoczVkTGlCTS1mNlEzRVVlSXMtbXpmRjljU1AzNlFLcnQtNUx1Z01xWXpmNV9IRGgxNEMzZzQtVUF6clJveTVSdmJ3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-24T07:00:00+00:00", "published_display": "24 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFAzNkNGUGdXcFZJeUtuVTlwenBZVXkzcmRScGNndVVLclBvYlp2WEtCS2kyNkY2MFY0dHh0Um1rbDVqeXNpaG9CXzctWHdmMU9rSmRHQmV1ZW9UUQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-11-16T08:12:22+00:00", "published_display": "16 Nov 2018 08:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON Stock Price and Chart \u2014 NASDAQ:ETON", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5lTGU2dS0xanZEdXFpWVJGWm9UMUVZZldYVFQtX1FGSG01Q2QxbDd4Q3BsQlozUTZIQ3ZIRXRxSUktTVdnMjIxQklnVUw2Zk5sekhzSVViNGRORmZn?oc=5", "source_name": "TradingView", "published_at": "2018-11-13T18:41:05+00:00", "published_display": "13 Nov 2018 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Eton Pharmaceuticals (ETON) Could Be 18% Undervalued As Valuation Questions Build", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-15T01:02:24+00:00", "published_display": "15 Jul 2026 01:02", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) CEO exercises options and RSUs, increasing stake", "summary": "Eton Pharmaceuticals President & CEO Sean Brynjelsen increased his stake in the company by exercising employee stock options for 200,000 shares and converting 27,500 restricted stock units (RSUs) into common stock. Following these transactions, Brynjelsen directly holds 1,061,194", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-5e6a44b6457d.html", "source_name": "Stock Titan", "published_at": "2026-07-14T21:20:11", "published_display": "14 Jul 2026 21:20", "sentiment": "positive", "sentiment_pct": 69, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (NASDAQ: ETON) CBO converts 10,000 RSUs into common shares", "summary": "Eton Pharmaceuticals' Chief Business Officer, David Krempa, has exercised 10,000 Restricted Stock Units (RSUs), converting them into an equal number of common shares. These RSUs were part of a larger grant from July 12, 2022, vesting in equal annual installments. Following this t", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-2ffb6208da81.html", "source_name": "Stock Titan", "published_at": "2026-07-13T20:14:17", "published_display": "13 Jul 2026 20:14", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Technical Signals Behind (ETON) That Institutions Follow", "summary": "This article analyzes Eton Pharmaceuticals Inc. (NASDAQ: ETON) using AI-generated signals for institutional trading strategies. It highlights weak near-term sentiment but strong mid and long-term outlooks, identifying compelling upside potential with no resistance levels above th", "url": "https://news.stocktradersdaily.com/news_release/8/The_Technical_Signals_Behind_ETON_That_Institutions_Follow_071326034803_1783928883.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T04:11:14", "published_display": "13 Jul 2026 04:11", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceutical(ETON.US) 10% Shareholder Sells US$4.77 Million in Common Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNUm8ta1BLOU56UVY3cmFIbVhwb0w3RDdmVDJTd1c1Y3ppdFJYWVluSWNsOHN6aFZwWXpOQUNPdGZEWGRRakFuUUc4R0lFQS1WQjZsVzNsYUtDWHZWNll1NWk0cFJ0VnBEYk5RNlZESnR4NGZYVG5JR3o5UVJUUEszdjI5cE9xRTl2aTBTRk44clNVSlo0WHozZGx6S0VzM21DRTloR3ZCVl8?oc=5", "source_name": "Moomoo", "published_at": "2026-07-07T23:27:56+00:00", "published_display": "07 Jul 2026 23:27", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opaleye management sells $4.77m Eton Pharmaceuticals (ETON) stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxQNmpTdm1JSmxFWm1JVWJ3aWpRLWlmVzJnSUdWdEh2ZUdGN09hZEJVSGYtQ29kVURHQnpjZjV2NHdiOE5PaVZfTXM0YWZCaTZnNEF5VGNETHpHeDFZaWtqV3NKN3lnblRfY29WMFVPVmJOMWt6ZnZ0X2dqSFJkcER3Q1Qwal96ZHBReTFJVFAxeG43dTZucUdkRllFZHltQ3c5YkRYdXc5YmVSUDI3U3Y4d0gtNXhvWnZLdTlhRDFXT0tWMktK?oc=5", "source_name": "Investing.com", "published_at": "2026-07-07T23:06:16+00:00", "published_display": "07 Jul 2026 23:06", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Opaleye trims Eton Pharmaceuticals (ETON) stake with open-market sales", "summary": "Opaleye Management Inc., a 10% owner of Eton Pharmaceuticals (ETON), reported open-market sales of 126,685 shares of common stock between July 2 and July 7, 2026. The shares were sold at weighted average prices between $37 and $38, reducing Opaleye L.P.'s holdings to 2,680,000 sh", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-f17613f340a2.html", "source_name": "Stock Titan", "published_at": "2026-07-07T22:39:37", "published_display": "07 Jul 2026 22:39", "sentiment": "negative", "sentiment_pct": 30, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals highlights its niche rare-disease focus as a specialty drug developer", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxPa3MxNDFDV3I4U28zQnRjZGZ3U1VwTkdHS0xBNFhFQ2hWSDZLX05OVWM2alozN3J1RFkySHlWeU9oa04zc3lwNEdyaE5qd2RoaXQ1ZW5FYVJlWFI2UTJkUjAzVzBSeDUwNXFidDN0c0xFdUJtLWZiN0FZaFdiVXdwTlljdTZ6ck1xT09wUUxmNmYxMGFyVS05T0VHRFFXbVNvblNmcy12WXktdHoxU0NJUzVuZDUzdWdKQXloNnB3dUFUQQ?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-07-07T18:00:21+00:00", "published_display": "07 Jul 2026 18:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals stock hits all-time high at 38.6 USD", "summary": "Eton Pharmaceuticals (ETON) stock reached an all-time high of $38.60, reflecting a 164.21% total return over the past year and nearly 80% revenue growth in the last twelve months. Despite an InvestingPro tip suggesting the stock might be overbought, the platform's Fair Value anal", "url": "https://www.investing.com/news/company-news/eton-pharmaceuticals-stock-hits-alltime-high-at-386-usd-93CH-4779704", "source_name": "Investing.com", "published_at": "2026-07-07T15:39:37", "published_display": "07 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) Grants Stock Awards, Is It Still 18% Below Fair Value?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-04T07:00:00+00:00", "published_display": "04 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Precision Trading with Eton Pharmaceuticals Inc. (ETON) Risk Zones", "summary": "This article analyzes Eton Pharmaceuticals Inc. (ETON) using AI models to provide precision trading strategies. It highlights strong sentiment across all horizons, suggesting an overweight bias, and details institutional trading strategies for long, breakout, and short positions ", "url": "https://news.stocktradersdaily.com/news_release/10/Precision_Trading_with_Eton_Pharmaceuticals_Inc._ETON_Risk_Zones_070226024002_1782974402.html", "source_name": "Stock Traders Daily", "published_at": "2026-07-03T01:40:53", "published_display": "03 Jul 2026 01:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Eton Pharmaceuticals, Inc. \u2013 NASDAQ:ETON", "summary": "This article provides financial context for Eton Pharmaceuticals, Inc. (NASDAQ: ETON), focusing on its enterprise value to forward revenue. It is presented within the framework of TradingView's platform, offering an overview of the company's financial data. The content is concise", "url": "https://www.tradingview.com/symbols/NASDAQ-ETON/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-01T12:10:37", "published_display": "01 Jul 2026 12:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) CBO awarded 10,000 restricted stock units", "summary": "Eton Pharmaceuticals' Chief Business Officer, David Krempa, was granted 10,000 restricted stock units (RSUs) as part of a compensation package. These RSUs will vest in four equal annual installments starting June 26, 2027, contingent on his continued employment. Following this gr", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-851ffc5cdabe.html", "source_name": "Stock Titan", "published_at": "2026-06-30T20:39:36", "published_display": "30 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Eton Pharmaceuticals Inc For: 30 June By Investing.com", "summary": "Investing.com reported on a Form 4 filing for Eton Pharmaceuticals Inc. as of June 30th. The brief article, published in the stock market section, mentioned the company's stock symbol ETON and its recent performance. It primarily serves as a notice of the regulatory filing and in", "url": "https://ca.investing.com/news/stock-market-news/form-4-eton-pharmaceuticals-inc-for-30-june-93CH-4714684", "source_name": "Investing.com Canada", "published_at": "2026-06-30T20:39:36", "published_display": "30 Jun 2026 20:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "regulatory", "event_label": "Regulatory and legal", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals stock hits all-time high at 36.97 USD", "summary": "Eton Pharmaceuticals (ETON) stock has reached an all-time high of $36.97, marking a 161.1% increase over the past year and pushing its market capitalization to $1.01 billion. This surge reflects strong investor confidence despite a mixed Q1 2026 earnings report where revenue beat", "url": "https://m.uk.investing.com/news/stock-market-news/eton-pharmaceuticals-stock-hits-alltime-high-at-3697-usd-93CH-4750895?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-30T18:40:44", "published_display": "30 Jun 2026 18:40", "sentiment": "positive", "sentiment_pct": 76, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Eton Pharmaceuticals, Inc. \u2013 BOATS:ETON", "summary": "This article focuses on the \"Enterprise value to revenue forward\" metric for Eton Pharmaceuticals, Inc. (ETON) listed on the Blue Ocean Alternative Trade System (BOATS). It provides a brief overview without detailed financial data or analysis. The content appears to be a stub or ", "url": "https://www.tradingview.com/symbols/BOATS-ETON/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T12:11:40", "published_display": "29 Jun 2026 12:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to sales forward of Eton Pharmaceuticals, Inc. \u2013 NASDAQ:ETON", "summary": "This article provides the \"Price to sales forward\" metric for Eton Pharmaceuticals, Inc. (NASDAQ: ETON). It specifically highlights the period, value, and change percentages for this financial indicator, noting that the market was closed at the time of publication with no recent ", "url": "https://www.tradingview.com/symbols/NASDAQ-ETON/financials-statistics-and-ratios/price-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-29T03:10:12", "published_display": "29 Jun 2026 03:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Eton Pharmaceuticals, Inc. \u2013 BOATS:ETON", "summary": "The article focuses on the \"Enterprise value to EBITDA forward\" metric for Eton Pharmaceuticals, Inc. (ETON) on the Blue Ocean Alternative Trade System (BOATS). It presents a financial snapshot within the TradingView platform, indicating a market closed status with no recent trad", "url": "https://www.tradingview.com/symbols/BOATS-ETON/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-28T21:40:48", "published_display": "28 Jun 2026 21:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON Forecast \u2014 Price Target \u2014 Prediction for 2027", "summary": "This article provides a forecast and price target for Eton Pharmaceuticals, Inc. (ETON) stock for 2027, based on analyst opinions. It includes current stock performance metrics, financial data, and answers frequently asked questions regarding ETON's stock price, volatility, marke", "url": "https://www.tradingview.com/symbols/NASDAQ-ETON/forecast-price-target/", "source_name": "TradingView", "published_at": "2026-06-26T22:12:00", "published_display": "26 Jun 2026 22:12", "sentiment": "positive", "sentiment_pct": 68, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON (ETON) Form 144: Affiliate sales include 25,000-share disposals", "summary": "Eton Pharmaceuticals (ETON) affiliate James R. Gruber filed a Form 144 revealing proposed and past sales of common stock, including three dispositions totaling 53,117 shares in June 2026. The filing also detailed various issuer-side equity transactions like stock option exercises", "url": "https://www.stocktitan.net/sec-filings/ETON/144-eton-pharmaceuticals-inc-sec-filing-fbfd04d5baab.html", "source_name": "Stock Titan", "published_at": "2026-06-26T20:39:28", "published_display": "26 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ETON)", "summary": "This article provides an overview of Eton Pharmaceuticals, Inc. (NASDAQ: ETON) stock, including its current price, market capitalization, and historical performance. It details financial actuals and estimates for earnings and revenue, analyst price targets, and future earnings re", "url": "https://www.tradingview.com/symbols/NASDAQ-ETON/forecast-actuals-and-estimates/", "source_name": "TradingView", "published_at": "2026-06-26T18:39:28", "published_display": "26 Jun 2026 18:39", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Eton Pharmaceuticals For: 25 June By Investing.com", "summary": "This article from Investing.com announces the Form 144 filing for Eton Pharmaceuticals on June 25, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity. The article itself is very brief, serving primarily as an announcement", "url": "https://ng.investing.com/news/stock-market-news/form-144-eton-pharmaceuticals-for-25-june-93CH-2575103", "source_name": "Investing.com Nigeria", "published_at": "2026-06-26T09:40:46", "published_display": "26 Jun 2026 09:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON (NASDAQ: ETON) notice: Director proposes sale of 25,000 shares", "summary": "A director at Eton Pharmaceuticals (NASDAQ: ETON) has filed a Form 144, indicating a proposed sale of 25,000 shares related to a stock option exercise on June 25, 2026. This filing also discloses previous sales by the same individual, James R. Gruber, including 25,000 shares on J", "url": "https://www.stocktitan.net/sec-filings/ETON/144-eton-pharmaceuticals-inc-sec-filing-3b41f6972d02.html", "source_name": "Stock Titan", "published_at": "2026-06-25T20:13:04", "published_display": "25 Jun 2026 20:13", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Inc (ETON) Institutional Confidence", "summary": "Eton Pharmaceuticals Inc (ETON) has an institutional shareholding score of 5.00, ranking 73rd in the Pharmaceuticals industry. The institutional shareholding proportion is 58.43%, a decrease of 4.32% quarter-over-quarter. James Simons is the largest institutional shareholder, hol", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-eton/sentiment", "source_name": "TradingKey", "published_at": "2026-06-24T10:40:48", "published_display": "24 Jun 2026 10:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider files to sell 25,000 shares via option exercise | ETON SEC Filing - Form 144", "summary": "An insider at Eton Pharmaceuticals (ETON) has filed a Form 144 to sell 25,000 shares through a stock option exercise scheduled for June 23, 2026. The filing also disclosed a prior sale of 3,117 shares on June 2, 2026, which generated $84,041.00. This administrative notice pertain", "url": "https://www.stocktitan.net/sec-filings/ETON/144-eton-pharmaceuticals-inc-sec-filing-aceef204cb1a.html", "source_name": "Stock Titan", "published_at": "2026-06-23T20:39:41", "published_display": "23 Jun 2026 20:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 144 Eton Pharmaceuticals For: 23 June By Investing.com", "summary": "This article from Investing.com reports on the filing of Form 144 by Eton Pharmaceuticals on June 23. It includes the stock symbol ETON and its performance, showing a 2.35% increase. The piece is brief and simply states the form filing event.", "url": "https://ca.investing.com/news/stock-market-news/form-144-eton-pharmaceuticals-for-23-june-93CH-4704566", "source_name": "Investing.com Canada", "published_at": "2026-06-23T10:42:00", "published_display": "23 Jun 2026 10:42", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc.(NasdaqGM:ETON) added to S&P Pharmaceuticals Select Industry Index", "summary": "Eton Pharmaceuticals, Inc. (NasdaqGM: ETON) has been added to the S&P Pharmaceuticals Select Industry Index. This news comes amidst recent insider stock sales, with one individual selling shares worth $1,623,795 on June 17, and another selling shares worth $3,229,923 on May 28. T", "url": "https://www.marketscreener.com/news/eton-pharmaceuticals-inc-nasdaqgm-eton-added-to-s-p-pharmaceuticals-select-industry-index-ce7f5cd3d88df620", "source_name": "www.marketscreener.com", "published_at": "2026-06-22T01:40:19", "published_display": "22 Jun 2026 01:40", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals director Adams sells 50,000 shares for $1.62m By Investing.com", "summary": "Jennifer McKie Adams, a director at Eton Pharmaceuticals (NASDAQ:ETON), sold 50,000 shares of the company\u2019s common stock for approximately $1.62 million on June 17, 2026, after exercising employee stock options. This transaction follows a 138% surge in ETON stock over the past ye", "url": "https://za.investing.com/news/insider-trading-news/eton-pharmaceuticals-director-adams-sells-50000-shares-for-162m-93CH-4333935", "source_name": "Investing.com South Africa", "published_at": "2026-06-18T19:39:18", "published_display": "18 Jun 2026 19:39", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals director Adams sells 50,000 shares for $1.62m", "summary": "Jennifer McKie Adams, a director at Eton Pharmaceuticals, sold 50,000 shares of the company\u2019s common stock for approximately $1.62 million on June 17, 2026. This sale followed Adams exercising employee stock options at a much lower price. The company recently reported mixed Q1 20", "url": "https://m.uk.investing.com/news/insider-trading-news/eton-pharmaceuticals-director-adams-sells-50000-shares-for-162m-93CH-4734078?ampMode=1", "source_name": "Investing.com", "published_at": "2026-06-18T04:10:06", "published_display": "18 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Director Sold Shares Worth Over $1.6M", "summary": "Jennifer Mckie Adams, a Director at Eton Pharmaceuticals, sold 50,000 shares of common stock on June 17, 2026, for a total of $1,623,795. The shares were sold in multiple trades at an average price of $32.4759 per share. Following this transaction, the director no longer directly", "url": "https://www.tradingview.com/news/tradingview:5f309a69213cd:0-eton-pharmaceuticals-director-sold-shares-worth-over-1-6m/", "source_name": "TradingView", "published_at": "2026-06-17T21:09:33", "published_display": "17 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) director exercises options, sells 50,000 shares in open market", "summary": "Eton Pharmaceuticals director Jennifer McKie Adams exercised employee stock options for 50,000 shares at $3.78 per share and immediately sold them in open-market transactions for a weighted average price of $32.4759 per share. The sale, totaling over $1.6 million, occurred throug", "url": "https://www.stocktitan.net/sec-filings/ETON/form-4-eton-pharmaceuticals-inc-insider-trading-activity-e69630c3c934.html", "source_name": "Stock Titan", "published_at": "2026-06-17T21:09:33", "published_display": "17 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Insider Sold Shares Worth $1,623,795, According to a Recent SEC Filing", "summary": "An insider at Eton Pharmaceuticals recently sold shares valued at $1,623,795, as disclosed in a recent SEC filing. This transaction follows another significant insider sale on May 28, 2026, where shares worth $3,229,923 were sold. The company, focused on rare disease treatments, ", "url": "https://www.marketscreener.com/news/eton-pharmaceuticals-insider-sold-shares-worth-1-623-795-according-to-a-recent-sec-filing-ce7f5cddd889f52d", "source_name": "www.marketscreener.com", "published_at": "2026-06-17T21:09:32", "published_display": "17 Jun 2026 21:09", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Insider Sold Shares Worth $3,229,923, According to a Recent SEC Filing", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/eton-pharmaceuticals-insider-sold-shares-075022089.html", "source_name": "MT Newswires", "published_at": "2026-05-28T07:50:22+00:00", "published_display": "28 May 2026 07:50", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "H.C. Wainwright Remains Bullish on Eton Pharmaceuticals\u2019 (ETON) Growth Strategy", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxNX2hZQjhadkNoeXBhTWM0dGo4S0dXamxXTzF3eWJHY2F4dFktdlR3MnZxSWhpSUQxNUFXejFQRUZNcy1VaERyTW5EeUo3aTBuYy0tcVFhSlVDMEUtdjRIbU9LQVh5QXc1NjJjVVFXV3ZDeHhxUlAtNko0RERwWGxGMDh5VmYxeUhsY1g1V25XemFjQ2c2OFYyOUNNMA?oc=5", "source_name": "Market source", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Obtains US Commercialization Rights to Impavido", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eton-pharmaceuticals-obtains-us-commercialization-210741609.html", "source_name": "MT Newswires", "published_at": "2026-05-19T21:07:41+00:00", "published_display": "19 May 2026 21:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO\u00ae (miltefosine)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eton-pharmaceuticals-expands-rare-disease-203000534.html", "source_name": "GlobeNewswire", "published_at": "2026-05-19T20:30:00+00:00", "published_display": "19 May 2026 20:30", "sentiment": "positive", "sentiment_pct": 58, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Announces U.S. Commercialization Rights for IMPAVIDO\u00ae, First FDA-Approved Oral Therapy for Leishmaniasis", "summary": "", "url": "https://news.google.com/rss/articles/CBMi-AFBVV95cUxPbTVKeTVLbktaUjBIVE14YU1kb2poeHNUYzNQM3AzZUZuM1hrYnpGd1dfbzc3NGo2UWpTSGVoeTVBZjJTbXdIejVnS0d0UjBoS1g2bFc3REJ2R2RDLXY5SEFtNmQ0YkVza2pwbldiVW9rclhHaG1EOXl0bkoyNURlcGV0dmF4YTN6cHhBdW80LUNWeW00b1BCQ2lFRkFBa1Q5RWE2QmpaYVNYWHlKV2E1Y1lXZ0hPb1c1dzNQV04wTlU3X0hyVnpjU1NfdU9tWFpEQmQ2MERoV3dYcURXeUl5a2VnUjF2dk5FMjlzd1VmQ3ZISGZJZUszSw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-19T07:00:00+00:00", "published_display": "19 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc. Just Missed EPS By 44%: Here's What Analysts Think Will Happen Next", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQZ0tPMGNUdWZQOEp6cDdIN2RlMGxrQl9HdDhkOTFtdnVEaVg1LXJDbFBaZ2p4NmZvVU5fdFZhdVJmbl9mZTVTak55NjhEQ01vZTl5MjFSendpOEFsN3FWRmM1T2RYLThqdERGQUVaV1cxMExZaTk5M25QSkRWWGJOMUUyTzVDMTJJbks0Mk1DQjI1Q3FpWDg3TE1sYmR4OXZZTFBJ?oc=5", "source_name": "Market source", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary", "summary": "", "url": "https://finance.yahoo.com/m/7d53c4ba-2771-3e8e-82e8-32ae12a0618f/eton-pharmaceuticals%2C-inc.-q1.html", "source_name": "Moby", "published_at": "2026-05-15T12:30:00+00:00", "published_display": "15 May 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Inc (ETON) Q1 2026 Earnings Call Highlights: Record Sales and Strategic ...", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/eton-pharmaceuticals-inc-eton-q1-050209376.html", "source_name": "GuruFocus.com", "published_at": "2026-05-15T05:02:09+00:00", "published_display": "15 May 2026 05:02", "sentiment": "positive", "sentiment_pct": 58, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Reports First Quarter 2026 Financial Results", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0wFBVV95cUxQVnRJMXJYSmlaSU9uVDc1ZXZoVVlXRV9VNVl2eENib1hjVllMRm9KelowbVYyNC1oamgwSWJLNjE2RjdTX3lfYnRxdGdSVFgtd1pzOUJuSDhHWTIwSnlCbEhKczdEcTctQlF2VDAtZ1FZYTZYTHNoM2xJZGd1NThxaDZvSjNlNDQ2SzBZdERsbGg4dnZyV2pReUt2em9DYjRUV1RRQ2d1TW9kMlA3QkNIYWMtYWhyZV9IYU9zUUlIMlpZd1pHV3pCMmNjUG11LVlmWjdN?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON PHARMACEUTICALS ($ETON) Releases Q1 2026 Earnings, Stock Rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxOSmwzX1FMLVJDZkY1SHdrZUhjTzRLVUpXVHItOUdIVFFCTDVKd0xxT3NpeXIwT3JpNFp1clZKR0E0M0NNcWRpVThQWktYVEI1OVk5U1hIZGR3dkVuVHNQaVcxZ09LYnhKQ0J6a3dMSWNxZDIweXhtbWlVOWtHZmZwMW1VN3hsdnB3Nnh6bU1rZTFfNEJGZUVkVG9vNllSSUZocUVKc1ZHLWsxZldC?oc=5", "source_name": "Quiver Quantitative", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals, Inc. (ETON) Misses Q1 Earnings Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxPV3p5ZUlmNkJpRmZNWkRHSU56eU42ZXVlRlY0NnVwN1E0am9XbFdOdjNYbjEwWjJDTVVCYno5VFM0MHNvQlhxZE40MFJuUDdXVjFmYzhRRTk3UEtiT2tpQWlNUlBTR0tJNGpGTmNzX2VycjRlOXdvWWxSbmVYb2tBUTVsTWI0NXN4bG1nNkpBcHRkbkxLZHBBMW05WHFWa3lzd0Rz?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Hikma Pharmaceuticals PLC stock (GB00B128J450): Dividend hike and $250M buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMixAFBVV95cUxNX2ZfWkxLZDAyQUZNRU55RXhPVHI4dlZrTVVuc3RlV01XV0Jqd21vSDdYU0l3QkJOejBicXhjRXhQcmpkZHlVQ3BsRFE5ZFFxbFV3MWgtLUpndEZKTm1vbTAwaGlYMHEzWVVjNDVUYjFpM1hJS0NRTjdCc3pOeG9VNlg0QThScXpuV3lYNi0xY2NXMnkwdkFMYU8xYWU0WTIyaVdESzRVV2wxaThRazh6bTZCV1RPMWpJWW0tZy1qQUJVNjh6?oc=5", "source_name": "Ad-hoc-news.de", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) Surges 19.8%: Is This an Indication of Further Gains?", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPUlhkUENyWlY2UzctUk5pd2c2OWNuRl9mUlZSWGRZX0JCN2xveExBRXF3clNMS0p4YzBDZWZKSEVJN0hlSVcwTVh3UGNOLU9hU1VBZ3B0bmNDbjBteHlYWWI5UGdoa01rNG5lVWpFaEcyMDdWeXNLaXA3QU1mYnFiYjFZNEF6elQ4OXFoRFhwZnlEeEpDcEh1UXEzREpuVHRFQ1E?oc=5", "source_name": "Market source", "published_at": "2026-05-04T07:00:00+00:00", "published_display": "04 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Hemangeol Deal Is Rewriting The Story For Eton Pharmaceuticals (ETON)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxPVWUxV2dlNTJVam53VnZFQlh3TFNpc0R3dnVXbE5WNWJYYkF0azA3czFGaDZHSi1EZFptQXhXU1lmclFuN3ZjeHBzMktHLWctSjYwemdBM0Q4Tk5ET2piZ0owY21JRzRmZnV1akV2Y2V0NmM4X01wLVBlMHh2ZEhsTUlQbUt6aW14bzhUOGczYjI0OFNSYVRfdVlZb0loM2RkTnc?oc=5", "source_name": "Market source", "published_at": "2026-05-03T07:00:00+00:00", "published_display": "03 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Hemangeol Deal Is Reframing The Eton Pharmaceuticals (ETON) Investment Story", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNMXdJeTBlU0d3X3JBYTYtb1FXOFc5R1gycnBEMWVJVzA3V1FEOWRHd0d2bjBCQk1nZlg2aV9jbTdQTkRQMjFEUnE5cHhleFBhb0YxeWZVQUhUSFFhRkY0UjlNWng4R0RENTZCMjVQTXA1bVlNRUphUndxMEk4NkNrMlNlRG44dzdFMlFsM1BHUGE5WHNDMFk3cmF2ZWtuUHBZSDdBNDNqQmNjd0o2NXlV?oc=5", "source_name": "Market source", "published_at": "2026-04-19T07:00:00+00:00", "published_display": "19 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Eton Pharmaceuticals (ETON) Story Is Shifting With Hemangeol And New Valuation Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxNN2x2dThDZzhqb0xfZFdhVjQ1MG14UnpIRGk2Yl9MQzhNdXpCYkdFVXF0cDlRTzFkdXY5RUF6SEh4SmhwaDExVWhJdWI2a2Y4X1VGV0Y5cEw2MzMtdGRwMXVHbjBrQW92S1BTRUhTTkt1MWdhSUoydVNQRXNUTmp4YmVaQ3pfRTdqNmxwRmk2Q1pEei1rSEk3eURtczE2amxCNW16SmN1cTY?oc=5", "source_name": "Market source", "published_at": "2026-04-05T07:00:00+00:00", "published_display": "05 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) Soars 6.7%: Is Further Upside Left in the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNRndoa0JMLURRdlNDemQ0U3BKN1M2aVZUMnNZTGdXZFQtajUxWGJMQ0UxZXEyOFZHUVJpNDhtQU1VRVRTUnVvUHR6ZUhIWTA1TjFFWkEzUTQxQ0IyTEJFbTBLb1Vkay1wd0tYVnluampkZDl4bVhKaHo1U3pWdzlORnNHd0xkSDJxTGx6VWhibXItNkJPVmJWQkdTZFl0bmc?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings call transcript: Eton Pharmaceuticals Q4 2025 beats EPS, stock rises", "summary": "", "url": "https://news.google.com/rss/articles/CBMiywFBVV95cUxQLVFBUTFOSU9JT0ViQUZNZjVJRjZTNC1rVm8tTTFDQk43MDBIRW9XVGpQRGIzUlZZZmtraTRmUGZYZHZFS0xmRFlobkpreXZzMnlEbGxicnRuQnhKOWY2NjBZcFVOemQ5SHBqTG15TDBNd1BQN2pJbVJKX1BQa3hPWVJ2NFZpa2VCeXFnbmpJNmVuTXlMcWt2S1VVcTVQTkJqMGl0UEdnYWZGaEt0TTVFYVBYVEs3T0ZaQkVQSUl0VzZWYWxRSEl4N1lldw?oc=5", "source_name": "Investing.com", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals Expands Rare Disease Portfolio with Acquisition of US Hemangeol Rights", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0AFBVV95cUxOOVFxZWxKakNERTRJY2liTjBJd1FscmtUMlNDRkhwT2ctY3hDVFRPSEtPZjUtT3VlR0R5a202aW10dUhnU0xUMWZBeWg2bVVhMTZxTmYzbGhacWVTQkJyTmVhUkNNY0JYcnQ1LUhBeXVNRDFadUNReHBTU2QzNFo3STRSeTUzYkQyZFZuYkZQdzRqWlB4eWZiTDREcXpvazRSRWJsY1B1TjdYVTZLaS1ma3RJQ0pjNFk5X2llYjN0RTlvY3VDaG1XYVlxNGtiY2VX?oc=5", "source_name": "Pharmaceutical Commerce", "published_at": "2026-03-04T08:00:00+00:00", "published_display": "04 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "We Might See A Profit From Eton Pharmaceuticals, Inc. (NASDAQ:ETON) Soon", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-13T08:00:00+00:00", "published_display": "13 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals: An Undervalued Small Cap With High Growth (NASDAQ:ETON)", "summary": "", "url": "https://news.google.com/rss/articles/CBMipgFBVV95cUxNOGxleHlzMVRmLTJJZUpQaG1wVy13SnZianVSbDlwbm9yMUtWU0pJeEZZNEduVkE2RUJJaTRkdy1DbzNmSjY1LS0zRi1EZGU3OVlCeUpvV01lQ1loTUZVbDZvNThoczVkTGlCTS1mNlEzRVVlSXMtbXpmRjljU1AzNlFLcnQtNUx1Z01xWXpmNV9IRGgxNEMzZzQtVUF6clJveTVSdmJ3?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-01-23T08:00:00+00:00", "published_display": "23 Jan 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Eton Pharmaceuticals (NASDAQ:ETON) Can Manage Its Debt Responsibly", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-09-24T07:00:00+00:00", "published_display": "24 Sep 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Eton Pharmaceuticals (ETON) Stock Price, News & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiWkFVX3lxTFAzNkNGUGdXcFZJeUtuVTlwenBZVXkzcmRScGNndVVLclBvYlp2WEtCS2kyNkY2MFY0dHh0Um1rbDVqeXNpaG9CXzctWHdmMU9rSmRHQmV1ZW9UUQ?oc=5", "source_name": "MarketBeat", "published_at": "2018-11-16T08:12:22+00:00", "published_display": "16 Nov 2018 08:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETON Stock Price and Chart \u2014 NASDAQ:ETON", "summary": "", "url": "https://news.google.com/rss/articles/CBMiXEFVX3lxTE5lTGU2dS0xanZEdXFpWVJGWm9UMUVZZldYVFQtX1FGSG01Q2QxbDd4Q3BsQlozUTZIQ3ZIRXRxSUktTVdnMjIxQklnVUw2Zk5sekhzSVViNGRORmZn?oc=5", "source_name": "TradingView", "published_at": "2018-11-13T18:41:05+00:00", "published_display": "13 Nov 2018 18:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [], "sector": []}, "total_fetched": 84, "total_relevant": 56, "sentiment_summary": {"positive": 17, "negative": 8, "neutral": 31, "score": 54, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 81, "events": [{"event": "general", "label": "Market update", "weight": 19.05, "count": 34}, {"event": "earnings", "label": "Earnings", "weight": 7.15, "count": 13}, {"event": "deals", "label": "Deals and strategy", "weight": 2.75, "count": 5}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.55, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 17, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 36.61, "latest_week": "2026-07-10", "one_week_move": -2.4, "four_week_move": 15.9, "twelve_week_move": 46.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.392766, "market_dynamics_buy_signal": false, "relative_strength": 51.715021, "fair_value_gap": 198.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 55.2453, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.4% over one week, +15.9% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 63, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 8}, {"label": "TradingView", "count": 8}, {"label": "Market source", "count": 8}, {"label": "Investing.com", "count": 5}, {"label": "simplywall.st", "count": 4}, {"label": "Stock Traders Daily", "count": 2}, {"label": "Ad-hoc-news.de", "count": 2}, {"label": "Investing.com Canada", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 56}, {"label": "Industry context", "count": 0}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 34}, {"label": "Earnings", "count": 13}, {"label": "Deals and strategy", "count": 5}, {"label": "Regulatory and legal", "count": 1}, {"label": "Analyst action", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "54/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "81/100 classification confidence."}, {"label": "Company focus", "value": "56", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.4% over one week, +15.9% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Eton Pharmaceuticals (ETON) Could Be 18% Undervalued As Valuation Questions Build"}], "updated_at": "2026-07-16T00:48:13.317772+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}